NO20100596L - Kinolonanaloger og fremgangsmater - Google Patents

Kinolonanaloger og fremgangsmater

Info

Publication number
NO20100596L
NO20100596L NO20100596A NO20100596A NO20100596L NO 20100596 L NO20100596 L NO 20100596L NO 20100596 A NO20100596 A NO 20100596A NO 20100596 A NO20100596 A NO 20100596A NO 20100596 L NO20100596 L NO 20100596L
Authority
NO
Norway
Prior art keywords
methods
quinolone analogs
present
compounds
quinolone
Prior art date
Application number
NO20100596A
Other languages
English (en)
Inventor
Jeffrey P Whitten
Michael K Schwaebe
Fabrice Pierre
Johnny Yasuo Nagasawa
Mustapha Haddach
Levan Darjania
Original Assignee
Cylene Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cylene Pharmaceuticals Inc filed Critical Cylene Pharmaceuticals Inc
Publication of NO20100596L publication Critical patent/NO20100596L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer nye kinolonforbindelser og farmasøytiskpreparat derav som kan hemme celleproliferasjonen og/eller fremkalle celle-apoptose. Foreliggende oppfinnelse tilveiebringer også metoder for fremstilling av slike forbindelser og preparater og metoder for anvendelse derav.
NO20100596A 2007-10-05 2010-04-26 Kinolonanaloger og fremgangsmater NO20100596L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US97804207P 2007-10-05 2007-10-05
US3868108P 2008-03-21 2008-03-21
US4593308P 2008-04-17 2008-04-17
PCT/US2008/078859 WO2009046383A1 (en) 2007-10-05 2008-10-03 Quinolone analogs and methods related thereto

Publications (1)

Publication Number Publication Date
NO20100596L true NO20100596L (no) 2010-06-10

Family

ID=40523786

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20100596A NO20100596L (no) 2007-10-05 2010-04-26 Kinolonanaloger og fremgangsmater

Country Status (18)

Country Link
US (2) US7928100B2 (no)
EP (2) EP3092901B1 (no)
JP (2) JP5824213B2 (no)
KR (2) KR101682867B1 (no)
CN (1) CN101888780B (no)
AU (1) AU2008308485B2 (no)
BR (1) BRPI0817806A2 (no)
CA (1) CA2701630C (no)
DK (1) DK3092901T3 (no)
ES (2) ES2791305T3 (no)
IL (2) IL204844A (no)
MX (1) MX2010003685A (no)
NO (1) NO20100596L (no)
NZ (1) NZ584892A (no)
PL (2) PL3092901T3 (no)
PT (2) PT3092901T (no)
RU (1) RU2549895C2 (no)
WO (1) WO2009046383A1 (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008131134A1 (en) * 2007-04-17 2008-10-30 Cylene Pharmaceuticals, Inc. Hydrazide compounds and uses thereof
BRPI0817806A2 (pt) * 2007-10-05 2014-10-07 Cylene Pharmaceuticals Inc Análogos de quinolona e métodos relacionados a estes
PL2470546T3 (pl) 2009-08-28 2013-12-31 Takeda Pharmaceuticals Co Związki heksahydrooksazynopterydynowe do zastosowania jako inhibitory MTOR
US8293925B2 (en) * 2009-09-21 2012-10-23 Chemocentryx, Inc. Pyrrolidinone carboxamide derivatives
WO2012148548A1 (en) 2011-02-25 2012-11-01 Takeda Pharmaceutical Company Limited N-substituted oxazinopteridines and oxazinopteridinones
EP2685976B1 (en) 2011-03-17 2017-12-27 Tel HaShomer Medical Research Infrastructure and Services Ltd. Quinolone analogs for treating autoimmune diseases
GB201206384D0 (en) * 2012-04-11 2012-05-23 Redx Pharma Ltd Antibacterial drug derivatives
CN104177379B (zh) * 2013-05-22 2016-12-28 中国科学院上海药物研究所 一种喹诺酮类化合物或其立体化学异构体、包含该化合物的药物组合物及其用途
CA2925698C (en) 2013-11-28 2021-11-09 Tel Hashomer Medical Research Infrastructure And Services Ltd. Rna polymerase i inhibitors and uses thereof
PE20170131A1 (es) * 2014-05-09 2017-03-19 Pimera Inc Composiciones novedosas usos y metodos para hacerlas
US9758518B2 (en) 2015-03-04 2017-09-12 Pimera, Inc. Compositions, uses and methods for making them
JP7017509B2 (ja) * 2015-11-20 2022-02-08 センワ バイオサイエンシズ インコーポレイテッド がんを治療するための四環式キノロン類似体の併用療法
TWI765848B (zh) * 2015-12-14 2022-06-01 生華生物科技股份有限公司 喹諾酮類似物及其鹽的結晶形式
WO2017105382A1 (en) * 2015-12-14 2017-06-22 Ryckman David M Crystalline forms of quinolone analogs and their salts
US9957282B2 (en) * 2015-12-14 2018-05-01 Senhwa Biosciences, Inc. Crystalline forms of quinolone analogs and their salts
EP4014967A1 (en) 2016-04-29 2022-06-22 Icahn School of Medicine at Mount Sinai Targeting the innate immunesystem to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
CA3057741A1 (en) 2017-03-28 2018-10-04 Pimera, Inc. Novel crystal forms of a pol1 inhibitor
US11071727B2 (en) 2018-01-26 2021-07-27 Northwestern University Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors
JP7445597B2 (ja) * 2018-02-15 2024-03-07 センワ バイオサイエンシズ インコーポレイテッド キノロン類似体及びそれらの塩、組成物、ならびにそれらの使用方法
WO2020051342A1 (en) * 2018-09-06 2020-03-12 Cornell University Methods for treating metastatic disease using ribosome biogenesis inhibitor cx 5461
BR112022002784A2 (pt) * 2019-08-14 2022-08-09 Senhwa Biosciences Inc Compostos tetracíclicos e sais do mesmo, composições e métodos para uso do mesmo
TW202115091A (zh) * 2019-08-14 2021-04-16 生華生物科技股份有限公司 喹啉類似物之結晶型及其鹽類、組合物、及彼等之使用方法
JP2020189888A (ja) * 2020-08-28 2020-11-26 センワ バイオサイエンシズ インコーポレイテッド キノロン類似体及びその塩の結晶形
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
CN114573604B (zh) * 2020-12-01 2024-06-18 中国科学院上海药物研究所 一类基于喹诺酮的化合物、其制备方法、包含其的药物组合物及其用途
CN118459539B (zh) 2021-03-19 2026-01-06 生物治疗探索股份有限公司 用于调节训练免疫的化合物及其使用方法
CN114409681A (zh) * 2022-03-18 2022-04-29 信义核新(北京)生物科技有限公司 用于治疗dna损伤修复缺陷肿瘤的喹诺酮类似物及其应用
CN121399139A (zh) * 2023-04-23 2026-01-23 信义核新(北京)生物科技有限公司 喹诺酮衍生物及其在抗肿瘤中的应用
WO2024222147A1 (zh) * 2023-04-23 2024-10-31 信义核新(北京)生物科技有限公司 喹诺酮类似物及其用途
WO2025114459A1 (en) * 2023-11-28 2025-06-05 Genome Therapeutics Ltd Tetracyclic compounds for use in antibody-drug conjugates for the treatment of cancer
WO2025133338A1 (en) * 2023-12-21 2025-06-26 Genome Therapeutics Ltd Quinolone derivatves against cancer

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EG20543A (en) * 1992-10-30 1999-07-31 Procter & Gamble Process for preparing of novel antimicrobial -5- (n-heterosubstituted amino) quinolones
DE60011755T2 (de) 1999-04-07 2005-06-30 The University Of Virginia Patent Foundation Calciumkanalblocker als antikrebsmittel
EP1453824A1 (en) * 2001-12-13 2004-09-08 Wockhardt Limited New generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
US6900224B2 (en) * 2002-07-31 2005-05-31 The Procter & Gamble Company Antimicrobial quinolones, their compositions and uses
NZ545970A (en) * 2003-09-22 2009-05-31 Janssen Pharmaceutica Nv 7-Amino alkylidenyl-heterocyclic quinolones and naphthyridones
AU2005286965B2 (en) * 2004-09-17 2009-10-22 Senhwa Biosciences, Inc. Quinolone analogs as cell proliferation inhibitors
PL1928887T3 (pl) * 2005-08-05 2015-05-29 Senhwa Biosciences Inc Sposoby otrzymywania analogów chinolonowych
WO2007022474A2 (en) * 2005-08-19 2007-02-22 Cylene Pharmaceuticals, Inc. HUMAN RIBOSOMAL DNA(rDNA) AND RIBOSOMAL RNA (rRNA) NUCLEIC ACIDS AND USES THEREOF
AR057555A1 (es) * 2005-10-27 2007-12-05 Merck Frosst Canada Ltd Un inhibidor de fosfodiesterasa-4 4-oxo-1-(3-sustituido fenil-1,4-dihidro-1,8-naftiridin-3-carboxamida y un procedimiento de preparacion del mismo
US20090291437A1 (en) * 2005-11-02 2009-11-26 O'brien Sean Methods for targeting quadruplex sequences
WO2008060693A2 (en) * 2006-05-17 2008-05-22 Cylene Pharmaceuticals, Inc. Tetracyclic imidazole analogs
WO2007146813A2 (en) 2006-06-08 2007-12-21 Cylene Pharmaceuticals, Inc. Pyridinone analogs as cell proliferation inhibitors
WO2007146831A2 (en) * 2006-06-08 2007-12-21 Cylene Pharmaceuticals, Inc. Quinolone analogs derivatized with sulfonic acid, sulfonate or sulfonamide
GB0701992D0 (en) 2007-02-02 2007-03-14 7Tm Pharma As Grehlin Receptor Modulators
WO2008131134A1 (en) * 2007-04-17 2008-10-30 Cylene Pharmaceuticals, Inc. Hydrazide compounds and uses thereof
BRPI0817806A2 (pt) * 2007-10-05 2014-10-07 Cylene Pharmaceuticals Inc Análogos de quinolona e métodos relacionados a estes

Also Published As

Publication number Publication date
KR101682867B1 (ko) 2016-12-05
EP2214491A4 (en) 2010-11-10
ES2791305T3 (es) 2020-11-03
JP5824213B2 (ja) 2015-11-25
JP2010540663A (ja) 2010-12-24
EP3092901B1 (en) 2020-04-29
PT3092901T (pt) 2020-05-21
WO2009046383A1 (en) 2009-04-09
CA2701630C (en) 2016-10-25
IL249906A0 (en) 2017-03-30
KR20160020578A (ko) 2016-02-23
RU2549895C2 (ru) 2015-05-10
IL204844A (en) 2017-01-31
EP2214491B1 (en) 2016-07-13
IL249906B (en) 2020-10-29
CA2701630A1 (en) 2009-04-09
NZ584892A (en) 2012-06-29
PL2214491T3 (pl) 2016-11-30
AU2008308485A1 (en) 2009-04-09
US7928100B2 (en) 2011-04-19
PL3092901T3 (pl) 2020-10-19
HK1150728A1 (en) 2012-01-13
CN101888780A (zh) 2010-11-17
EP2214491A1 (en) 2010-08-11
CN101888780B (zh) 2014-08-13
US8853234B2 (en) 2014-10-07
JP2014159474A (ja) 2014-09-04
IL204844A0 (en) 2010-11-30
KR20100064392A (ko) 2010-06-14
EP3092901A1 (en) 2016-11-16
BRPI0817806A2 (pt) 2014-10-07
DK3092901T3 (da) 2020-05-18
PT2214491T (pt) 2016-10-25
KR101601332B1 (ko) 2016-03-08
US20110218184A1 (en) 2011-09-08
RU2010117225A (ru) 2011-11-10
ES2582662T3 (es) 2016-09-14
MX2010003685A (es) 2010-06-02
US20090093455A1 (en) 2009-04-09
AU2008308485B2 (en) 2014-08-07

Similar Documents

Publication Publication Date Title
NO20100596L (no) Kinolonanaloger og fremgangsmater
CY1120935T1 (el) Νεες συνθεσεις, χρησεις και μεθοδοι για την παρασκευη αυτων
CY1122330T1 (el) Συνθεσεις δισκιων μηλεϊνικης νερατινιμπης
CL2014000746A1 (es) Compuestos derivados de 3-pirimidin-4-il-oxazolidin-2-ona y sus sales, como inhibidores de las proteinas idh mutantes; composicion farmaceutica que los comprende, utiles para el tratamiento de trastornos de la proliferacion celular tal como el cancer.
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
UA114901C2 (uk) Інгібітори асс та їх застосування
WO2017050791A8 (en) New bicyclic compounds as dual atx/ca inhibitors
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
BR112012008385A2 (pt) inibidores de p13 cinase e uso dos mesmos.
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CO2017011151A2 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
MX378998B (es) Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares.
TR201900274T4 (tr) Geliştirilmiş adenovirüs formülasyonları.
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
MX351165B (es) Antagonistas de trpv1.
MX381487B (es) Ciertos inhibidores de la proteina quinasa.
CO2017011152A2 (es) Nuevos compuestos bicíclicos como inhibidores duales de atx / ca.
NO20090596L (no) Antivirale fosfinatforbindelser
CL2015001279A1 (es) Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras.
CL2014001060A1 (es) Compuestos derivados de aril-quinolina; proceso de obtencion; composicion farmaceutica que los comprende y uso en el tratamiento o profilaxis de la diabetes tipo 2, la aterosclerosis, cancer, entre otras enfermedades.
WO2016141042A3 (en) Novel compositions, uses and methods for making them
GT201500143A (es) Composiciones que comprenden vortioxetina y donepezilo campo tecnico
MX374654B (es) Compuestos útiles para inhibir ror-gamma-t.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application